GeoVax Labs, Inc. announced that members of its executive medical and scientific team will deliver presentations at the upcoming World Vaccine Congress Europe 2025, scheduled for October 13–16, 2025, at the RAI Amsterdam Convention Centre. The presentations will focus on interim safety data and special-populations insights for GEO-CM04S1, the company's multi-antigen COVID-19 vaccine being evaluated in immunocompromised patients.
Mark J. Newman, PhD, GeoVax Chief Scientific Officer, will participate in the Special Populations Workshop during the Pre-Congress Workshops on Monday, October 13. His presentation, titled "Vaccine design to address the immunocompromised: T-lymphocyte driven…Balanced immunity - Broader specificity - Increased memory," will address the challenges of vaccine development for vulnerable populations, including those with compromised immune systems. This focus is particularly important given the documented limitations of current authorized COVID-19 vaccines in providing adequate protection for immunocompromised individuals.
Kelly T. McKee, Jr., MD, MPH, GeoVax Chief Medical Officer, will present a scientific poster highlighting interim safety and reactogenicity data for GEO-CM04S1 in adults with hematologic malignancies receiving cellular therapies. The poster will be displayed in the Poster Zone, Exhibition Hall from October 14–16 and represents crucial safety information for a patient population that often experiences suboptimal responses to conventional vaccines.
The World Vaccine Congress Europe convenes global experts across science, clinical development, manufacturing, and public health. More details about the congress can be found at https://www.terrapinn.com/conference/world-vaccine-congress-europe. David Dodd, GeoVax President & CEO, emphasized the importance of this international gathering, stating, "We look forward to highlighting the progress of our multi-antigen GEO-CM04S1 in immunocompromised populations, where the need for more effective vaccine options remains urgent."
GEO-CM04S1 represents a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials. The vaccine is being evaluated as a primary vaccine for immunocompromised patients, including those with hematologic cancers, as a booster vaccine in patients with chronic lymphocytic leukemia, and as a more robust, durable COVID-19 booster among healthy patients who previously received mRNA vaccines. This multi-faceted approach addresses significant gaps in current COVID-19 vaccination strategies, particularly for populations that remain vulnerable despite existing vaccine options.
The development of effective vaccines for immunocompromised individuals carries broader implications for public health and pandemic preparedness. Immunocompromised patients not only face higher risks of severe COVID-19 outcomes but may also serve as reservoirs for viral evolution and transmission. Successful vaccine development for these populations could reduce healthcare burdens and improve outcomes for some of the most vulnerable members of society. The data presentation at this prestigious international conference marks an important step in validating approaches that may extend beyond COVID-19 to other infectious disease threats.
For additional information about GeoVax's clinical programs and development pipeline, visit https://www.geovax.com. The company's focus on multi-antigen vaccines and targeted approaches for special populations represents an important advancement in the ongoing evolution of vaccine technology and accessibility.
